Business
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
GENEVA, May 28, 2025--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
About this update from Alcon Ag
[{"type":"image","alt":"TRYPTYR® (acoltremon ophthalmic solution) 0.003% logo","displaySize":"","headline":null,"caption":"TRYPTYR® (acoltremon ophthalmic solution) 0.003% logo","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":201,"url":"https://media.zenfs.com/en/business-wire.com/97c4b54d80d6e2d2a271b79681e2038b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EmmsZzIlAlntJIX8TQKqEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/97c4b54d80d6e2d2a271b79681e2038b","width":480,"height":201}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":202,"url":"https://media.zenfs.com/en/business-wire.com/e46d29d20ebb21fe6c78005077368150"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4_3LWnKGIsFvLiI4gK24tw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e46d29d20ebb21fe6c78005077368150","width":480,"height":202}}},{"type":"list","items":[{"val":[{"type":"text","content":"In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2","length":98,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)3","length":138,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product4","length":156,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":392,"olType":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"GENEVA, May 28, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-i...